Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials

Award Number: U01CA295226
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/19/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2030

Group Awards By:

View Award Description

Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials - PROJECT SUMMARY/ABSTRACT The core aim of this study is to systematically investigate and mitigate the impact of preanalytical variables on the accuracy and reliability of targeted, multiple reaction monitoring mass spectrometry (MRM-MS)-based immune protein measurements in cerebrospinal fluid (CSF) from pediatric brain tumor patients participating in clinical trials. Recently, immune therapies such as immune checkpoint inhibitors or intrathecal (i.e., introduced directly into the cerebrospinal fluid) delivery of chimeric antigen receptor T-cell (CAR-T) therapies have shown promise for treating poor prognosis pediatric brain tumors, yielding improved outcomes for some. However, more research is needed to optimize safety, to identify patients most likely to respond, to monitor response in real time, & to understand immune response timing and mechanisms (pharmacodynamics) to develop strategies to increase efficacy. This study will: (i) identify and characterize sources of CSF biospecimen preanalytical variation affecting MRM-based assay performance for quantifying immunomodulatory protein biomarkers in CSF, (ii) develop, validate, and disseminate a preanalytical quality control standard operating protocol (SOP) to counteract preanalytical variation impact on the performance of MRM assays quantifying immunomodulatory proteins in CSF, and (iii) validate the biospecimen SOP through real-world testing by analyzing prospectively collected clinical trial samples at two CLIA (Clinical Laboratory Improvement Amendments) labs to demonstrate harmonization. Tools established through this work will enhance the interpretation of clinical trial outcomes through data reliability & provide valuable insights into the immunological mechanisms underlying the effects of immune-based treatments in pediatric brain tumor patients enrolled in clinical trials. The work also has broader significance for immune analyses of CSF in primary and metastatic adult brain tumors, as well as in neuroinflammatory disorders where immune activation either causes or contributes to the pathogenesis (e.g., multiple sclerosis, Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, stroke and traumatic brain injuries myelitis).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $405,509 )
2026	2026	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Treatment Research	000	2	3/3/2026	NON-COMPETING CONTINUATION	$405,509
														Subtotal = $405,509

Issue Date FY: 2025 ( Subtotal = $440,171 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Treatment Research	000	1	3/19/2025	NEW	$440,171
														Subtotal = $440,171

Grand Total All Awards = $845,680

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials

Award Number: U01CA295226

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/19/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer